Among the tested compounds, YMGKI-2 (Ergosta-4, 6, 8(14), 22-tetraen-3-one; Ergone) (Figure 1A)) treatment significantly reduced the ALDH enzymatic activity of HNSCC cell lines (SAS and OECM1) in a dose-dependent manner (Figure 1B and 1C). Here, LDHA is linked to head and neck squamous cell carcinoma.